FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.


FLUIDIGM CORP Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Fluidigm Announces Exchange of Convertible Notes SOUTH SAN FRANCISCO,…
To view the full exhibit click here

About FLUIDIGM CORPORATION (NASDAQ:FLDM)

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

FLUIDIGM CORPORATION (NASDAQ:FLDM) Recent Trading Information

FLUIDIGM CORPORATION (NASDAQ:FLDM) closed its last trading session up +0.05 at 6.86 with shares trading hands.

An ad to help with our costs